The other problem is that TV Advertising has been dropped from both Abbvie and Lilly. This could impact sales, however it would drastically improve Lilly's margins.
It could be in their best interest to keep sales below $50m. Their margins are probably still quite large, particularly with the drop in advertising.
If they keep the product at below $200m in annual sales, it prevents them paying a $50m payout, they also keep margins tight and market share looks to be stable. It's smart, but no good for Acrux....
ACR Price at posting:
82.0¢ Sentiment: Buy Disclosure: Held
